CS/BSE/NSE/PR/2016-2017

October 18, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,
Sub: Press Release

With reference to above subject, please find enclosed Press Release of our
company titled Suven Life Sciences secures two (2) Product Patents in Europe
and Israel
This is for your information and records
Thanking You,
Yours faithfully,
For Suven Life Sciences Limited
K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 24 1 10 TG 1 98 9 P L C 00 9 7 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release
Suven Life Sciences secures two (2) Product Patents in Europe and Israel
HYDERABAD, INDIA (October 18, 2016) Suven Life Sciences Ltd (Suven) announces today that
the grant of one (1) product patent from Europe (2513085) and one (1) product patent from
Israel (224652) corresponding to the New Chemical Entities (NCEs) for the treatment of
disorders associated with Neurodegenerative diseases and these Patents are valid through
2030 and 2029 respectively.
The granted claims of the patents are from the mechanism of action include the class of
selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as
therapeutic agents and are useful in the treatment of cognitive impairment associated with
neurodegenerative disorders like Alzheimers disease, Attention deficient hyperactivity disorder
(ADHD), Huntingtons disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, Suven has a total of twenty three (23) granted patents from Europe
and twelve (12) granted patents from Israel. These granted patents are exclusive intellectual
property of Suven and are achieved through the internal discovery research efforts. Products
out of these inventions may be out-licensed at various phases of clinical development like at
Phase-I or Phase-II.
We are very pleased by the grant of these patents to Suven for our pipeline of molecules in
CNS arena that are being developed for cognitive disorders with high unmet medical need with
huge market potential globally says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2
undergoing candidate SUVN-502, two Phase 1 completed candidates SUVN-G3031 and SUVND4010 and one IND ready compound SUVN-911 for Alzheimers disease, Schizophrenia and
Major Depressive Disorder (MDD). In addition to that the Company has nine (9) internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development targeting
conditions such as ADHD, dementia, depression, Huntingtons disease, Parkinsons disease and
pain.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may make
our products/services offerings less competitive; Suven may not undertake to update any forward-looking
statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th FloorRoad No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 24 1 10 TG 1 98 9 P L C 00 9 7 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com